Proto-Oncogene Proteins c-kit
"Proto-Oncogene Proteins c-kit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
| Descriptor ID |
D019009
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.050 D12.776.543.750.630.124 D12.776.543.750.705.852.150.100 D12.776.543.750.750.400.200.170 D12.776.624.664.700.183
|
| Concept/Terms |
Proto-Oncogene Proteins c-kit- Proto-Oncogene Proteins c-kit
- Proto Oncogene Proteins c kit
- c-kit, Proto-Oncogene Proteins
- Stem Cell Factor Receptor
- SCF Receptor
- p145 c-kit
- c-kit, p145
- p145 c kit
- p145(c-kit)
- p145c-kit
- p145c kit
- CD117 Antigen
- Antigens, CD117
- CD117 Antigens
- Proto-Oncogene Protein c-kit
- Proto Oncogene Protein c kit
- c-kit, Proto-Oncogene Protein
- c-kit Protein
- c kit Protein
- kit Proto-Oncogene Protein
- Proto-Oncogene Protein, kit
- kit Proto Oncogene Protein
- Receptor, Stem Cell Factor
- Proto-Oncogene Protein kit
- Proto Oncogene Protein kit
- c-kit Receptor
- c kit Receptor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-kit".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-kit".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-kit" by people in this website by year, and whether "Proto-Oncogene Proteins c-kit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 3 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 5 | 3 | 8 |
| 2015 | 0 | 3 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-kit" by people in Profiles.
-
Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 2018 06 12; 23(11):3392-3406.
-
Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
-
Loss of c-Kit and bone marrow failure upon conditional removal of the GATA-2 C-terminal zinc finger domain in adult mice. Eur J Haematol. 2016 Sep; 97(3):261-70.
-
Development of the fetal bone marrow niche and regulation of HSC quiescence and homing ability by emerging osteolineage cells. Cell Rep. 2014 Oct 23; 9(2):581-90.
-
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013 Oct; 92(10):1335-43.
-
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65.
-
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013 Mar; 88(3):219-24.
-
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol. 2012 Sep 11; 7:154.
-
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
-
Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis. Hum Pathol. 2012 Dec; 43(12):2223-8.